9 d. ago 90% Early Detection Rate: BioMark's Breakthrough Lung Cancer Test Gets Patents in $1.5B Asian Market

90% Early Detection Rate: BioMark's Breakthrough Lung Cancer Test Gets Patents in $1.5B Asian Market  Stock Titan

Other

9 d. ago Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer

Nuvation Bio Surges on Japanese Approval of Ibtrozi for Lung Cancer  StocksToTrade

Other

1 week ago Nuvation Bio Soars As Japan Approves Ibtrozi for Advanced Lung Cancer

Nuvation Bio Soars As Japan Approves Ibtrozi for Advanced Lung Cancer  StocksToTrade

Other

2 w. ago How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer

How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer  simplywall.st

Other

2 w. ago Nuvation Bio stock gains as Japan approves IBTROZI for lung cancer

Nuvation Bio stock gains as Japan approves IBTROZI for lung cancer  Investing.com

Other

2 w. ago NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy

NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy  simplywall.st

Other

2 w. ago Nuvation Bio Says Japan Approves IBTROZI For ROS1+ Advanced Non

Nuvation Bio Says Japan Approves IBTROZI For ROS1+ Advanced Non-small Cell Lung Cancer Treatment  Nasdaq

Other

2 w. ago Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer  Yahoo Finance

Other

3 w. ago Novocure obtains approval for Optune Lua device in Japan to treat NSCLC

Novocure obtains approval for Optune Lua device in Japan to treat NSCLC  Medical Device Network

Other

3 w. ago Novocure’s electric fields device approved for treating lung cancer in Japan

Novocure’s electric fields device approved for treating lung cancer in Japan  Mugglehead Magazine

Other

3 w. ago NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo

NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo  simplywall.st

Other

3 w. ago Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)  Business Wire

Other